Evidence mapPaperPMID 39009504Full record

ArticleCNS neuroscience & therapeutics2024

Alterations in metabolome and lipidome in patients with in-stent restenosis.

Ziqi Xu, Chenye Mou, Renjie Ji, Hanfen Chen, Yuge Ding, Xiaoyi Jiang, Fanxia Meng, Fangping He, Benyan Luo, Jie Yu

Abstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziqi XuDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Chenye MouDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.ORCID 0000-0002-3467-237X
Renjie JiDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Hanfen ChenDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yuge DingDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Xiaoyi JiangDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Fanxia MengDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Fangping HeDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Benyan LuoDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.ORCID 0000-0002-9892-5778
Jie YuDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.ORCID 0000-0003-4488-6010

Funding

the Natural Science Foundation of Zhejiang pvovince LGF20H090010
6 · The paper itself

Abstract

contextIn-stent restenosis (ISR) can lead to blood flow obstruction, insufficient blood supply to the brain, and may even result in serious complications such as stroke. Endothelial cell hyperproliferation and thrombosis are the primary etiologies, frequently resulting in alterations in intravascular metabolism. However, the metabolic changes related to this process are still undermined.

objectiveWe tried to characterize the serum metabolome of patients with ISR and those with non-restenosis (NR) using metabolomics and lipidomics, exploring the key metabolic pathways of this pathological phenomenon.

resultsWe observed that the cysteine and methionine pathways, which are associated with cell growth and oxidative homeostasis, showed the greatest increase in the ISR group compared to the NR group. Within this pathway, the levels of N-formyl-l-methionine and L-methionine significantly increased in the ISR group, along with elevated levels of downstream metabolites such as 2-ketobutyric acid, pyruvate, and taurocholate. Additionally, an increase in phosphatidylcholine (PC) and phosphatidylserine (PS), as well as a decrease in triacylglycerol in the ISR group, indicated active lipid metabolism in these patients, which could be a significant factor contributing to the recurrence of blood clots after stent placement. Importantly, phenol sulfate and PS(38:4) were identified as potential biomarkers for distinguishing ISR, with an area under the curve of more than 0.85.

conclusionsOur study revealed significant metabolic alterations in patients with ISR, particularly in the cysteine and methionine pathways, with phenol sulfate and PS(38:4) showing promise for ISR identification.

Indexed as

MetabolomeStentsAgedCoronary RestenosisFemaleHumansLipid MetabolismLipidomicsMaleMetabolomicsMiddle Agedbiomarkersin‐stent restenosislipidomicsmetabolomicsmethionine

Identifiers

PMID39009504
PMCPMC11249805

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.